A baseline protein signature of patients that were PD-1 resistant as analyzed via mass spectrometry, was characterized by complement, acute phase, and wound healing molecules in metastatic melanoma patients receiving PD-1 blocking antibody [70]. This evidence concerns the gene PDCD1 and metastatic melanoma.